Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 2 1Phase 1 1

Status

Recruiting 21Unknown 16Not yet recruiting 10Active not recruiting 10Completed 9Terminated 6Withdrawn 2

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6Observational 2

Sponsor

Cancer Type

Breast 6Gastrointestinal 1

Conditions

Breast Neoplasms 989Neoplasms 848Carcinoma, Non-Small-Cell Lung 842Prostatic Neoplasms 527Neoplasm Metastasis 500Leukemia, Myeloid, Acute 488Melanoma 453Colorectal Neoplasms 446Multiple Myeloma 440Lung Neoplasms 419Pancreatic Neoplasms 352Recurrence 350Lymphoma 349Ovarian Neoplasms 341Lymphoma, Non-Hodgkin 327Leukemia 323Leukemia, Lymphocytic, Chronic, B-Cell 301Precursor Cell Lymphoblastic Leukemia-Lymphoma 271Carcinoma, Renal Cell 256Head and Neck Neoplasms 246Brain Neoplasms 243Carcinoma, Hepatocellular 234Squamous Cell Carcinoma of Head and Neck 231Glioblastoma 231Myelodysplastic Syndromes 229Lymphoma, Large B-Cell, Diffuse 228Lymphoma, Follicular 219Colonic Neoplasms 191Stomach Neoplasms 182Rectal Neoplasms 175

Interventions

Trastuzumab 3pertuzumab 2Docetaxel 2palbociclib 1Protons 1Paclitaxel 1Letrozole 1Fulvestrant 1Enfuvirtide 1Doxorubicin 1Cyclophosphamide 1Capecitabine 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Terminated × Interventional × HER2-positive Breast Cancer × Clear all
NCT07166367 2025-09-10

Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer

National Cancer Centre, Singapore

Phase 2 Terminated
3 enrolled
Breast

HER2-positive Breast Cancer

NCT05511844 2025-07-04

Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

Orum Therapeutics USA, Inc.

Phase 1 Terminated
25 enrolled
Breast

HER2-positive Breast Cancer

NCT05555251 2024-12-16

CONTRAST

BioInvent International AB

Phase 1/2 Terminated
18 enrolled
BreastGastrointestinal

HER2-positive Breast Cancer

NCT03709082 2024-03-05

Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

University of Kansas Medical Center

Phase 1/2 Terminated
3 enrolled
Breast

HER2-positive Breast Cancer

NCT02379585 2018-04-24

STEFNE

Western Regional Medical Center

Phase 1/2 Terminated
8 enrolled 1 chart
Breast

HER2-positive Breast Cancer

NCT02345772 2018-02-20

Neohttp

Western Regional Medical Center

Phase 1/2 Terminated
4 enrolled 1 chart
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡